151. Synthesis and biological investigation of triazolopyridinone derivatives as potential multireceptor atypical antipsychotics
- Author
-
Chunhui Wu, Wenqiang Shi, Yongjian Liu, Feipu Yang, Jingshan Shen, Zhen Wang, Song Wu, Wei Zheng, Yang He, and Yu Wang
- Subjects
Models, Molecular ,Pyridines ,medicine.medical_treatment ,Clinical Biochemistry ,Pharmaceutical Science ,Pharmacology ,01 natural sciences ,Biochemistry ,Partial agonist ,Structure-Activity Relationship ,In vivo ,Dopamine receptor D2 ,Drug Discovery ,medicine ,Humans ,Receptor, Serotonin, 5-HT2A ,Antipsychotic ,Receptor ,Molecular Biology ,Dose-Response Relationship, Drug ,Molecular Structure ,010405 organic chemistry ,Chemistry ,Organic Chemistry ,Trazodone ,Triazoles ,0104 chemical sciences ,010404 medicinal & biomolecular chemistry ,Receptor, Serotonin, 5-HT1A ,Molecular Medicine ,Antidepressant ,5-HT1A receptor ,Antipsychotic Agents ,medicine.drug - Abstract
A series of triazolopyridinone derivatives originating from the antidepressant trazodone was designed and pharmacologically evaluated. Most of the compounds with a multireceptor functional profile exhibited high potency at the D2, 5-HT1A, and 5-HT2A receptors. Compounds S1, S3, S9 and S12 were selected for further evaluation of druggable potential. Among these compounds, S1, as a D2 receptor partial agonist, demonstrated very potent inhibition of quipazine-induced head-twitch response, which validated its 5-HT2A receptor antagonistic efficacy in vivo. S1 also demonstrated a dose-dependent effect on PCP-induced hyperactivity when administered orally. Thus, S1 endowed with a triazolopyridinone scaffold represents a valuable lead for the development of novel atypical antipsychotics.
- Published
- 2020